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Introduction
Solid lipid nanoparticles (SLN) firstly introduced in 1991 
by Muller and Gasco, represent an alternative carrier system to 
traditional colloidal carriers such as emulsions, liposomes and 
polymeric micro/nanoparticles [1]. 
SLNs are sub-micron colloidal carriers ranging from 50 to 
1000 nm, which are composed of physiological lipid, dispersed in 
water or in aqueous surfactant solution [2,3]. They offer unique 
properties such as small size, large surface area, high drug loading 
and are attractive for their potential to improve performance of 
pharmaceuticals [4-6]. Furthermore, they also have the ability to 
encapsulate both hydrophobic and hydrophilic drugs, improving 
thus their physico-chemical and pharmacokinetics profile [1,5]. 
Solid lipid nanoparticles have many advantages namely low 
cost of ingredients, ease of preparation and scale-up, high drug 
payload, no biotoxicity of the carrier, possibility of controlled drug 
release and targeting [5,6]. 
There are various method of preparation for SLNs, each one 
providing special features, advantages and limitations. These 
methods include High pressure homogenization, ultra sonication 
Techniques, Solvent evaporation method, solvent ejection method 
(solvent displacement method), Solvent emulsification-diffusion 
method, supercritical fluid method, micro emulsion based 
method, spray drying method, Double emulsion method and 
Precipitation technique [7-11]. 
Oral chemotherapy is a key step towards chemotherapy at home, 
a dream of cancer patients, which will radically change the clinical 
practice of chemotherapy and greatly improve the quality of life of 
the patients [12]. However, this route sounds very challenging due 
to the low aqueous solubility, poor intestinal permeability, high 
level of P-glycoprotein (P-gp) efflux and pre-systemic metabolism 
of most of anticancer drugs being currently used. Many research 
works have showed that nanotechnology based drug delivery 
have the ability to encapsulate various anticancer drugs, offering 
thus a valuable mean to overcome the above issues [13-15]. 
Topotecan (9-[(dimethyl amino) methyl]-10-hydroxy- (20S) - 
camptothecin hydrochloride) is one of the two camptothecin 
analogues currently approved for clinical application by FDA for 
the treatment of refractory ovarian cancer and/or small-cell lung 
cancer, which are resistant to conventional chemotherapeutic 
agents. In addition, the combination of topotecan with other 
standard chemotherapeutic agents is progressively being used 
for optimized therapy [16,17]. Nowadays, there are considerable 
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Abstract
The objective of this research work was to formulate and evaluate solid lipid 
nanoparticles of anticancer drug topotecan hydrochloride in order to sustain 
its release and therefore improve its therapeutic outcomes. SLNs were prepared 
by hot micro emulsion method using glyceryl monostearate as lipid carrier and 
Tween 80 as surfactant in specific proportions. FT-IR and DSC studies revealed 
that there was no interaction between drug and lipid. The effect of drug: lipid 
ratio, surfactant concentration, speed and time of homogenizer on drug release, 
particle size and EE were studied. The results of particle size, encapsulation 
efficiency and in vitro drug release at 12hr fell between 111.9 nm and 255nm, 
65.12% and 77.63%, and 72.31 and 79.79% respectively. Optimized formulation 
showed release of drug up to 73.47 % at 12 hrs, entrapment efficiency of 81.75% 
and particle size of 158.0 nm. The analysis of 3-D graphs revealed that parameters 
such as drug: lipid ratio and time of homogenization have a profound effect on 
both encapsulation efficiency and cumulative drug release. Scanning electron 
microscopy studies showed particles with disuniform surface and shape. The drug 
release from optimized formulation was found to fit best into first order kinetic 
model. It also showed almost linear regression in Higuchi’s plot suggesting that 
diffusion is one of the mechanisms for drug release and n value of Korsmeyer-
Peppas plot was found to be 0.716 indicating that the drug release did not follow 
fickian diffusion controlled mechanism. 
Keywords: Solid lipid nanoparticles; Glyceryl monostearate; Surfactant; 
Encapsulation efficiency; In vitro release studies 
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data in the literature addressing the toxicity level of topotecan. 
Some studies showed topotecan as being relatively well tolerated 
at low dose basis with non hematologic toxicities that include 
nausea, vomiting, and dyspnea and these side effects are generally 
mild to moderate in severity [18,19]. Nevertheless, when the 
standard dosing regimen is considered (Topotecan 1.5 mg/m2 
on days 1 to 5 of a 21-day cycle), the drug has been associated 
with increased bone marrow toxicity and severe haematological 
toxicities, limiting the practicality of using the drug in patients 
with low performance status [20].
Preclinical studies demonstrated greater antitumor efficacy 
with prolonged low-dose exposure to topotecan, and in animal 
models, low-dose prolonged exposure resulted in less toxicity. 
Therefore, increased antitumor efficacy and decreased toxicity 
could be achieved by prolonged exposure of tumour tissues to 
the drug [21,22]. Many studies have reported the encapsulation 
of Topotecan within liposomes, but there are barely any reports 
on preparation of topotecan loaded solid lipid nanoparticles 
as an attempt to sustain or prolong its release following oral 
administration. Hot micro emulsion based method is a highly 
accessible method which does not require sophisticated 
equipment to produce solid lipid nanoparticles. Hence, the 
overall aim of this work was to formulate and evaluate topotecan 
hydrochloride loaded solid lipid nanoparticles in order to achieve 
sustained release profile and therefore improved efficacy of 
topotecan and decrease the toxicity level of this drug as well. 
Materials and Methods
Materials
Topotecan hydrochloride was gifted sample of Strides arcolab 
limited, Bangalore, India. Glycerol monostearate was purchased 
from Aka fine chemicals, Bangalore, India. Tween 80 was 
purchased from S.D Fine chemicals, Mumbai, India. Poloxamer 
188 (Pluronic F-68) was purchased from HiMedia laboratory, 
pvt ltd, Mumbai, India. Potassium dihydrogen phosphate was 
procured from Qualigens Fine Chemicals, Mumbai, India. Sodium 
hydroxide was obtained from Rolex Chemical Industries, Mumbai, 
India. 
Methods
Fourier Transform Infrared Spectroscopy (FT-IR)
The drug excipients interaction studies were carried out by 
scanning A) Pure drug B) Drug + Glyceryl monostearate C) Drug + 
Tween 80 using FT-IR spectrophotometer (Bruker, α-E: ATR model, 
Germany) in the range of 4000-500 cm-1 and any incompatibility 
associated with the drug and excipients were studied. 
Differential scanning calorimetry
The Differential Scanning Calorimetry was employed as tool 
to investigate the physico-chemical incompatibility between 
the drug and commonly used excipients which might affect the 
stability of the drug by chemical and physical interactions thus 
posing a threat to the stability or bioavailability. DSC was carried 
out using a DSC Q200 (TA instruments, US). A mass of 5 mg 
samples were accurately weighted, sealed in an aluminium pan 
and equilibrated at 25 _C, which were subjected to a heating run 
over the temperature range of 25–250oC, except for GMS whose 
we scanned up to 100oC only.
X- Ray diffraction
The X-Ray diffraction of Topotecan hydrochloride formulation 
was done to find out any change in the crystallinity of the drug 
during microencapsulation by using Siemens DX500. PXRD studies 
were performed by exposing the samples to CuKα radiation (45 
kV, 40 mA) and scanning from 5° to 50°, 2θ at a step size of 0.017° 
and scan step time of 25 s. 
Preparation of topotecan loaded SLNs using micro emulsion 
method
Solid lipid of topotecan hydrochloride was prepared by hot 
micro emulsion based method. Briefly, the drug (10mg) was 
previously dissolved in methanol and dispersed in melted lipid 
(glyceryl monostearate), and then the mixture was dispersed in 
a hot aqueous solution with surfactant(tween 80) concentration 
ranging from 1% to 2%, by high –speed stirring, using an Ultra-
Turrax homogenizer at specific rpm for an appropriate period of 
time. The resulting dispersion was then cooled and each sample 
was diluted with water before the particle size was measured 
using dynamic laser light scattering apparatus at 25 ºC. 
Mean particle size, polydispersity index (PdI) and zeta 
potential
Dynamic light scattering (DLS) was used to assess the mean 
particle size and PdI of the solid lipid nanoparticles dispersions. 
Samples were diluted (1:50) with distilled water and analysed 
using a Zetasizer Nano S (Malvern Instruments, UK). Zeta 
potential was determined from electrophoretic mobility using a 
Zetasizer Nano ZS (Malvern Instruments, UK). 
Percentage yield
 To obtain the percentage yield, the obtained solid lipid 
nanoparticles were lyophilised and then weighted. % yield was 
calculated by using following formula.
 
Determination of drug content 
The amount of SLNs equivalent to 5 mg Topotecan 
hydrochloride were accurately weighed and then added to 100 ml 
of methanol. The samples were heated at 65ºC to melt the carrier. 
Heating was done for 20 min. The solutions were centrifuged at 
20000 rpm for 30 min. The supernatant was collected and the 
drug content was estimated by UV Spectrophotometer at 382 nm.








      




estimated amount of drug in taken SLN
Theoritical amount of drug in SLN
= ×
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Determination of Entrapment efficiency (EE)
SLNs equivalent to 50 mg of topotecan hydrochloride were 
accurately weighed and then added to 100 ml of methanol. 
The solutions were kept shaking for 1 hr. Then the solutions 
were centrifuged at 20000 rpm for 30 min. The supernatant 
was collected and the drug content was estimated by UV 
Spectrophotometer at 382 nm [20]
Where;
Wi is the amount of drug added to SLNs
Wf is the amount of free drug detected in the supernatant. 
In vitro diffusion study
The diffusion study of prepared solid nanoparticles was 
performed using cellulose dialysis membrane with a molecular 
weight cut-off of 12,000 Da and phosphate buffer (pH 6.8) at 370C 
± 0.50C. The Franz diffusion cell of 140 ml capacity was used. The 
composition equivalent to 3.5 mg of topotecan hydrochloride was 
applied on the membrane and diffusion study was performed 
over a period of 12 hrs. The samples (3 ml) were withdrawn at 
1, 2, 3, 4, 5, 6, 7, 8, and 12 hour and fresh medium were added 
to maintain sink condition. The collected samples were filtered 
through 0.22 μl filter and analysed at 382 nm by using UV/VIS 
Spectrophotometer. The obtained data were subjected to release 
kinetics studies by applying four kinetics models to the data in 
order to determine the best fitting equations [23,24]
Zero order equation: Q = Q0 – k0t
First order equation: ln = lnQ – k1t
Higuchi equation: Q = k2t1/2
Korsmeyer peppas equation: Q/Q0 = ktn
K0 to K2 were release rate constant, Q/Q0 was fraction of drug 
released at time t, K was constant n was diffusion constant that 
indicates general operating release mechanism. 
Optimization
The formulations were designed based on Taguchi OA design 
and then evaluated for the response. Four input factors were 
studied at three levels (34) throughout the preparation process to 
determine their effect on three responses, namely mean particle 
size, encapsulation efficiency and drug at 1hr, 8 hr and 12 hr. 
The input factors being selected are the following: Drug to lipid 
ratio (1/20, 10/250, and 10/300), concentration of surfactant 
(1%, 1.5%, 2%) speed (14000RPM, 16000RPM, 18000 RPM) and 
time of homogenization (5min, 10min and 15min). The response 
values were subjected to multiple regression analysis to find out 
the relationship between the input factors used and the response 
values obtained. Therefore, the objective of the optimization 
process was to quantify the effect of the above factors on the solid 
lipid nanoparticles. The multiple regression analysis was done 
using design expert 9.0.4 software, which is specially meant for 
this optimization process. 
In the numerical optimization techniques, the desirability 
approach was used to generate the optimum settings for the 
formulation. For the optimized formulation, the particles size was 
kept at the targeted value, the drug release at 1st hr was kept at 
minimum, the drug release at 8th hr was kept at minimum, and 
drug release at 12th hr was kept at minimum. The encapsulation 
efficiency was also kept at maximum. The optimized formulation 
was prepared according to predicted model and evaluated for 
responses. The result of the optimized formulation has been 
further compared with the predicted model values. 
Scanning electron microscope
The solid sample was sputter-coated using a thin gold–
palladium layer under an argon atmosphere using a gold sputter 
module in a high-vacuum evaporator (JFC-1100 fine coat ion 
sputter; Tokyo, Japan). These coated samples were then scanned 
and photomicrographs were taken at an acceleration voltage of 
5 kV. 
Statistical analysis
Data were analysed with the help of one-way analysis of 
variance (ANOVA) test and parameters were significant for the p 
< 0.05. 
Results and Discussion
Fourier Transform Infra-red (FT-IR) studies.
The spectrum obtained from FT infrared spectroscopy studies 
at wavelength from 4000cm-1- 500cm-1 are shown in Figure1 
Characteristic peaks in the region of 1732.90 cm-1, 1468.06 cm-
1, 3308.54 cm-1, 1111.22 cm-1, 1457.83 cm-1 were found to be 
observed in physical mixtures which were identical to that of 
the pure drug; this confirmed the intactness of the drug in the 
physical mixture. 
Differential Scanning Calorimetry (DSC) studies and XRD 
studies. 
In DSC studies melting peak appeared at 191⁰C for topotecan 
hydrochloride and 53.04⁰C for glyceryl monostearate as showed 
in Figure 2 Slight shift in peak position for both topotecan 
and glyceryl monostearate was observed in physical mixture 
indicating that there is no interaction between topotecan and 
lipid. Seemingly, the absence of Topotecan endotherm peak 
in thermo grams of SLN formulation argues that majority of 
Topotecan was present in amorphous form within the lipid 
matrix. After SLNs formation, reduction in crystallinity (reduced 
number and intensity of peaks) was observed in PXRD spectrum 
for the drug. This simply proves presence of molecular level 
dispersion and therefore the efficiency of the dispersion of 
the drug within the lipid carrier after SLN formation and also 
strengthens the hypothesis that crystallinity of Topotecan gets 
reduced significantly in SLN formation. PXRD data are presented 
in Figure 3. 
Evaluation and characterization of Topotecan SLNs
Particles size, % drug content and encapsulation efficiency
The prepared formulations have been analysed for drug 
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and polydispersity index. Under the optimum preparation 
conditions, small lipid nanoparticles with a relatively uniform 
size distribution were obtained. Figure 4 The mean dynamic 
light scattering particle diameters fell between 111.9 nm and 255 
nm with PDI values below 0.3 indicating fair size distributions 
[25,26]. Encapsulation of water soluble or hydrophilic drug into 
a solid lipid matrix is one of the challenges associated with this 
type of formulation and requires appropriate approach to address 
it [27] So far, the optimized formulation has shown up to 81.75% 
encapsulation efficiency. The relatively high level of encapsulation 
plays an important role in the achievement of desirable prolonged 
release effect. Thus, it can be concluded that hot micro emulsion 
method and excipients used in this study are suitable to produce 
TPT-SLNs. Table 1 Presents the results of particles size, % drug 
content and encapsulation efficiency of all the formulations. 
Figure 1: FTIR spectra of TPT (A), Physical mixture of TPT+GMS (B), physical mixture of TPT+Tween 80 (C) and physical mixture of TPT + Pluronic 
F-68 (D).
Figure 2: DSC thermo grams of TPT (A), GMS (B), physical mixture of TPT and GMS (C) and TPT-SLNs (D).
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Figure 3: XRD of topotecan pure drug (left) and TPT-SLNs formulation (right).
Figure 4: Dynamic light scattering mean particles size of TPT-SLNS optimized formulation. 
In-vitro drug release studies and drug release kinetics
The in vitro release of Topotecan hydrochloride from the 
prepared solid lipid nanoparticle formulations and pure drug 
was studied in pH 6.8 phosphate buffer as that is the intestinal 
pH. The drug release was measured for 12 hr. The pure drug has 
showed complete release at around 3 hours. This is not surprising 
since the drug is not in a sustained formulation. In contrary, for 
the TPT-SLN formulation, prolonged release was noticed, which 
suggests that the drug was significantly encapsulated insight the 
lipid matrix [28].The cumulative drug release for the optimized 
formulation was about 73.47% at 12 hr Figure 5. 
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Table 1: Mean diameter, polydispersity index (PDI), entrapment efficiency (EE), and drug content (DC).
Sample Series Mean Diameter (In Nm) PDI EE (%W/W) DC (%W/W)
F1 180 0.366 69.25 96.86
F2 151 0.353 71.24 93.21
F3 158 0.375 70.44 90.12
F4 255.5 0.296 74.44 95.43
F5 213.3 0.337 65.12 94.32
F6 143.5 0.351 73.24 97.35
F7 137.5 0.314 77.63 92.13
F8 114.4 0.341 68.85 90.67
F9 111.9 0.287 67.92 91.74
F10 (optimized) 158 0.301 81.75 97.82
Drug release mechanisms and kinetics are the two important 
characteristics of a delivery system in describing the drug 
dissolution or diffusion profile. It is now well known that 
qualitative and quantitative changes in the formulation but also 
in the processing conditions may alter drug release and in vivo 
performances of a pharmaceutical system. The mathematical 
models methods represent one the rational approaches to 
assess and predict the in vivo bio-performance of new delivery 
systems. In this perspective, the drug release data of TPT-SLN 
formulations were fitted into different models like zero order, first 
order, Higuchi equation and Korsmeyer-peppas. The correlation 
coefficient value (R2) was used as an indicator to find the best 
fitting equation for the prepared TPT-SLN formulations. The drug 
release from optimized formulation was found to fit best into 
first order kinetic model, which means that the drug release is 
proportional to the amount of drug remaining inside the delivery 
system. It also showed almost linear regression in Higuchi’s plot 
suggesting that diffusion is one of the mechanisms for drug release 
and n value of Korsmeyer-Peppas plot was found to be 0.716 
indicating that the drug release did not follow fickian diffusion 
controlled mechanism. The non-Fickian diffusion might suggest 
that rates of solvent penetration and drug release are in the same 
range. Based on these results we can conclude that the prepared 
TPT-SLNs formulation fit for a diffusion matrix formulation. The 
result of release kinetics studies are presented Figure 6 
Effect of formulation and process variables on mean particles 
size
Particle size is a critical characteristic of nanoparticles and 
by definition differentiates them from micro particles. Particle 
size and particle size distribution play an important role in the 
biological performance of the nanoparticles [29]. Nowadays, 
Figure 5: In vitro release data of TPT-SLNs formulation and TPT pure drug. 
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Nanoparticles are becoming very attractive because of their 
important and unique features, such as their surface to mass ratio 
that is much larger than that of other particles, and their ability to 
adsorb and carry a broad range of medical relevant compounds like 
drugs and proteins [30]. Both formulation and process variable 
might affect the mean particle size and size distribution of solid 
lipid nanoparticles during the production. Therefore, the effect of 
drug to lipid ratio and concentration of surfactant on the particle 
size was studied. The model was found to be significant with an 
F value of 8.05 (p < 0.0339). Figure 7 represents the observed 
response values compared to that of predicted values. From the 
3 D graph it was found that 1.5 % of tween 80 concentration gave 
the smaller particles size. Moreover, the particle size turned to 
decrease with increase in the speed of stirring and the particle 
size was found to be increased with increase in the lipid content. 
Figure 6: Release kinetics of different TPT-solid lipid nanoparticles formulations.
Figure 7: 3-D graph showing effect of drug: lipid ratio and Tween 80 conc on mean particle size (R1)
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Effect of formulation and process variables on 
encapsulation efficiency 
One of the major challenges in the development of nanocarriers 
based drug delivery is to engineer a system that can effectively 
encapsulate drugs at high concentration. The encapsulation 
offers several advantages such as protection, improvement of 
intrinsic properties of the encapsulated molecules, targeting 
properties, and sustained release effect [31].For this reason, the 
effect of formulation and process variables on encapsulation 
efficiency was investigated. The model was found to be significant 
with an F value of 49.19 (p < 0.0201). Figure 8 represents the 
observed response values compared to that of predicted values. 
The 3-D graph shows that the encapsulation efficiency increased 
with increase of lipid amount and concentration of surfactant. 
However, the concentration of surfactant affects much less on the 
%EE as compare to the effect of lipid amount. 
Effect of formulation and process variables on drug 
release profile
There is a considerable number of studies which present solid 
lipid nanoparticles as tool to achieve sustained or prolong release 
of encapsulated molecules. In this particular case, a couple of 
studies have demonstrated the relevance of prolonged exposure 
of topoisomerase I inhibitors might be beneficial in improving the 
clinical efficacy of such drug [32,33]. From this basis, the attempt 
in this work was to sustain the release of topotecan in order to 
optimize its therapeutic outcome following oral administration. 
Therefore, the effect of formulation and process variables on 
the release pattern was studied. The model was found to be 
significant with an F value of 6.44 (p < 0.0321), F value of 21.50 
(p < 0.0451), and F value of 5.21 (p < 0.0479) respectively for 
release 1hr, 8hr, and 12hr. From the 3-D graphs Figure 9 it can be 
learned that the increase in the time of homogenization results 
in a significant raise of 1hr release. The explanation may be as 
the time homogenization increases, the particles size goes smaller 
and therefore increase the rate of drug release. The 8hr release 
decrease with an increase of lipid concentration. 
The optimize formulation was evaluated and the experimental 
values were compared to the predicted ones as illustrated in 
Figure 10. The summary of Anova results is presented in Table 2. 
Scanning electron microscope
The particles size and shape may affect several properties 
of nanotherapeutics systems such as drug release rate, ability 
to interact with biological systems etc. Therefore, the surface 
morphology and size of lyophilized TPT- Solid lipid nanoparticles 
was studied using scanning electron microscope. The Figure 11 
shows particles with quite disuniform surface and shape. The size 
of the particles from SEM was slightly different in comparison to 
dynamic light scattering result. This might be due to influence of 
the lyophilisation process since for SEM analysis we have used 
lyophilised samples.
Figure 8: 3-D graph showing effect of drug: lipid ratio and Tween 80 conc on encapsulation efficiency (R2)
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Figure 9: 3-D graph showing effect of input variables on drug release 1 hr, 8hr and 12hr.
Conclusion
This study has demonstrated the feasibility of the development 
of topotecan loaded solid lipid nanoparticles using Taguchi design 
approach. The sustained release property of this formulation as 
well as the in vitro release kinetics model were illustrated. The 
analysis of 3-D graphs has provided a deep understanding of the 
effect of input variables on the selected responses. Therefore, it 
can be concluded that the method and optimization approach 
adopted throughout this study are suitable for producing 
topotecan-SLNs.
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Figure 10: The comparison between predicted and experimental value for Particles size (1), Encapsulation efficiency (2), Release 1hr (3), Release 
8hr (4), and Release 12hr (5). 
Figure 11: SEM of optimized formulation.
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Table 2: Summary of Anova results in analysing lack of fit (LOF).
Source Sum square d.f. Mean Square F value Probability >F
Mean particle size      
Model 15621.77 4 3905.44 8.05 0.0339*
Residual 1939.75 4 484.94   
Total 17561.52 8    
Encap. Efficiency      
Model 112.15 6 18.69 49.19 0.0201*
Residual 0.76 2 0.38   
Total 112.91 8    
Release 1hr      
Model 77.16 2 38.58 6.44 0.0321*
Residual 35.97 6 6   
Total 113.13 8    
Release 8hr      
Model 165.17 6 27.53 21.5 0.0451*
Residual 2.56 2 1.28   
Total 167.73 8    
Release 12hr      
Model 29.86 2 14.93 5.26 0.0479*
Residual 17.02 6 2.84   
Total 46.88     
Note: (*) Significant (p < 0.05).
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